Targeting a new cell type, Th22, a great promise in eczema: Expert post from Emma Guttman-Yassky, MD, PhD: At our academic institution we have shown that eczema is associated with a new lymphocyte cell, Th22, that produces an inflammatory product termed interleukin 22 associated with the activity of eczema. We now have received NIH funding to perform a clinical trial in patients with eczema with an anti IL-22 antagonist, ILV-094. Since IL-22 is also involved in the thickening of the epidermal barrier, this treatment might prove to be very effective for the chronic phase of the disease. This clinical trial will be conducted at two medical centers: Mount Sinai and the Rockefeller University Hospital in NYC (Clinicaltrials.gov). Would you be willing to be part of the new developments in eczema? Would you be willing to participate in trials that can change eczema?
Posted on: Wed, 25 Sep 2013 16:39:22 +0000
Trending Topics
Recently Viewed Topics
© 2015